{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:15:33Z","timestamp":1792181733460,"version":"4.4.0"},"reference-count":71,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&amp;D Program of China","doi-asserted-by":"publisher","award":["2021YFC2300200"],"award-info":[{"award-number":["2021YFC2300200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&amp;D Program of China","doi-asserted-by":"publisher","award":["82122039"],"award-info":[{"award-number":["82122039"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key R&amp;D Program of China","doi-asserted-by":"publisher","award":["2022 ZL01"],"award-info":[{"award-number":["2022 ZL01"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2021YFC2300200"],"award-info":[{"award-number":["2021YFC2300200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82122039"],"award-info":[{"award-number":["82122039"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2022 ZL01"],"award-info":[{"award-number":["2022 ZL01"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Project of the Ministry of Education","award":["2021YFC2300200"],"award-info":[{"award-number":["2021YFC2300200"]}]},{"name":"Science and Technology Innovation Project of the Ministry of Education","award":["82122039"],"award-info":[{"award-number":["82122039"]}]},{"name":"Science and Technology Innovation Project of the Ministry of Education","award":["2022 ZL01"],"award-info":[{"award-number":["2022 ZL01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Since its emergence in 2019, the rapid spread of SARS-CoV-2 led to the global pandemic. Recent large-scale dengue fever outbreaks overlapped with the COVID-19 pandemic, leading to increased cases of co-infection and posing severe public health risks. Accordingly, the development of effective combined SARS-CoV-2 and dengue virus (DENV) vaccines is necessary to control the spread and prevalence of both viruses. Methods: In this study, we designed Sindbis virus (SINV) replicon-based SARS-CoV-2 and DENV chimeric vaccines using two delivery strategies: DNA-launched self-replicating RNA replicon (DREP) and viral replicon particle (VRP) systems. Results: Cellular and animal experiments confirmed that the vaccines effectively produced viral proteins and elicited strong immunogenicity. These vaccines induced robust immune responses and neutralizing activity against live SARS-CoV-2, DENV1, and DENV2 viruses. In addition, passively transferred sera from BALB\/c mice immunized with these vaccines into AG129 mice provided significant protection against lethal DENV2 challenge. The transferred sera protected the mice from physical symptoms, reduced viral loads in the kidney, spleen, liver, and intestine, and prevented DENV2-induced vascular leakage in these tissues. Conclusions: Therefore, combined vaccines based on the SINV replicon system are promising candidates for pandemic control. These results lay a foundation for further development of a safe and effective combination vaccine against SARS-CoV-2 and DENV.<\/jats:p>","DOI":"10.3390\/vaccines12111292","type":"journal-article","created":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T04:53:05Z","timestamp":1731991985000},"page":"1292","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sindbis Virus Replicon-Based SARS-CoV-2 and Dengue Combined Vaccine Candidates Elicit Immune Responses and Provide Protective Immunity in Mice"],"prefix":"10.3390","volume":"12","author":[{"given":"Yihan","family":"Zhu","sequence":"first","affiliation":[{"name":"State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8237-9215","authenticated-orcid":false,"given":"Wenfeng","family":"He","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Hu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiahua","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhu","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3892-480X","authenticated-orcid":false,"given":"Yuan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan 430072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-021-04188-6","article-title":"The emergence, genomic diversity and global spread of SARS-CoV-2","volume":"600","author":"Li","year":"2021","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/nrdp.2016.55","article-title":"Dengue infection","volume":"2","author":"Guzman","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Vicente, C.R., Herbinger, K.-H., Fr\u00f6schl, G., Malta Romano, C., de Souza Areias Cabidelle, A., and Cerutti Junior, C. (2016). Serotype influences on dengue severity: A cross-sectional study on 485 confirmed dengue cases in Vit\u00f3ria, Brazil. BMC Infect. Dis., 16.","DOI":"10.1186\/s12879-016-1668-y"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Guo, C., Zhou, Z., Wen, Z., Liu, Y., Zeng, C., Xiao, D., Ou, M., Han, Y., Huang, S., and Liu, D. (2017). Global Epidemiology of Dengue Outbreaks in 1990-2015: A Systematic Review and Meta-Analysis. Front. Cell. Infect Microbiol., 7.","DOI":"10.3389\/fcimb.2017.00317"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Fried, J.R., Gibbons, R.V., Kalayanarooj, S., Thomas, S.J., Srikiatkhachorn, A., Yoon, I.K., Jarman, R.G., Green, S., Rothman, A.L., and Cummings, D.A. (2010). Serotype-specific differences in the risk of dengue hemorrhagic fever: An analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl. Trop. Dis., 4.","DOI":"10.1371\/journal.pntd.0000617"},{"key":"ref_6","unstructured":"Kalayanarooj, S., and Nimmannitya, S. (2000). Clinical and Laboratory Presentations of Dengue Patients with Different Serotypes, WHO Regional Office for South-East Asia."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/s41564-019-0376-y","article-title":"Past and future spread of the arbovirus vectors Aedes aegypti and Aedes albopictus","volume":"4","author":"Kraemer","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"110498","DOI":"10.1016\/j.isci.2024.110498","article-title":"Mapping environmental suitability changes for arbovirus mosquitoes in Southeast Asia: 1960\u20132020","volume":"27","author":"Hou","year":"2024","journal-title":"iScience"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41564-019-0476-8","article-title":"The current and future global distribution and population at risk of dengue","volume":"4","author":"Messina","year":"2019","journal-title":"Nat. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Lenharo, M. (2023). Dengue is breaking records in the Americas\u2014What\u2019s behind the surge?. Nature, ahead of print.","DOI":"10.1038\/d41586-023-02423-w"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Naddaf, M. (2023). Dengue is spreading in Europe: How worried should we be?. Nature, ahead of print.","DOI":"10.1038\/d41586-023-03407-6"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1126\/science.adj4427","article-title":"Indian Ocean temperature anomalies predict long-term global dengue trends","volume":"384","author":"Chen","year":"2024","journal-title":"Science"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S1473-3099(24)00095-1","article-title":"Risk of dengue spread is high globally, says WHO","volume":"24","author":"Burki","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_14","first-page":"100274","article-title":"Fast expansion of dengue in Brazil","volume":"12","author":"Codeco","year":"2022","journal-title":"Lancet Reg. Health Am."},{"key":"ref_15","unstructured":"WHO (2024). Dengue and Severe Dengue, World Health Organization. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dengue-and-severe-dengue."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/jmv.26269","article-title":"Coinfection, coepidemics of COVID-19, and dengue in dengue-endemic countries: A serious health concern","volume":"93","author":"Miah","year":"2020","journal-title":"J. Med. Virol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2340","DOI":"10.1002\/rmv.2340","article-title":"SARS-CoV-2 and dengue virus co-infection: Epidemiology, pathogenesis, diagnosis, treatment, and management","volume":"33","author":"Prapty","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"103670","DOI":"10.1016\/j.amsu.2022.103670","article-title":"The current dengue outbreak amidst COVID-19 pandemic in Pakistan; a major threat to Pakistan\u2019s healthcare system","volume":"78","author":"Ahmad","year":"2022","journal-title":"Ann. Med. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/MS9.0000000000000418","article-title":"Year-round dengue fever in Pakistan, highlighting the surge amidst ongoing flood havoc and the COVID-19 pandemic: A comprehensive review","volume":"85","author":"Tabassum","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_20","first-page":"101041","article-title":"COVID-19 and dengue coinfection in Latin America: A systematic review","volume":"49\u201350","author":"Barboza","year":"2022","journal-title":"New Microbes New Infect."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"taaa114","DOI":"10.1093\/jtm\/taaa114","article-title":"COVID-19 and dengue co-infection in a returning traveller","volume":"27","author":"Epelboin","year":"2020","journal-title":"J. Travel Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41591-024-02798-x","article-title":"Severe disease during both primary and secondary dengue virus infections in pediatric populations","volume":"30","author":"Aggarwal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"751","DOI":"10.4269\/ajtmh.21-0586","article-title":"Impact of Recent SARS-CoV-2 Infection on the Course and Severity of Dengue in Children: A Prospective Observational Study from North India","volume":"105","author":"Ravikumar","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.csbj.2020.12.037","article-title":"Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?","volume":"19","author":"Nath","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(20)30158-4","article-title":"Covert COVID-19 and false-positive dengue serology in Singapore","volume":"20","author":"Yan","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2444","DOI":"10.1093\/cid\/ciaa1207","article-title":"Potential Antigenic Cross-reactivity Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Dengue Viruses","volume":"73","author":"Lustig","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Cheng, Y.-L., Chao, C.-H., Lai, Y.-C., Hsieh, K.-H., Wang, J.-R., Wan, S.-W., Huang, H.-J., Chuang, Y.-C., Chuang, W.-J., and Yeh, T.-M. (2022). Antibodies against the SARS-CoV-2 S1-RBD cross-react with dengue virus and hinder dengue pathogenesis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.941923"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e1219","DOI":"10.1093\/cid\/ciaa1895","article-title":"Previous Dengue Infection and Mortality in Coronavirus Disease 2019 (COVID-19)","volume":"73","author":"Silvestre","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41392-021-00750-w","article-title":"The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41577-022-00720-5","article-title":"Estimating disease severity of Omicron and Delta SARS-CoV-2 infections","volume":"22","author":"Sigal","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: Potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/S0140-6736(04)15788-7","article-title":"Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: Implications for virus fusogenic mechanism and identification of fusion inhibitors","volume":"363","author":"Liu","year":"2004","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/s41422-022-00746-3","article-title":"A variant-proof SARS-CoV-2 vaccine targeting HR1 domain in S2 subunit of spike protein","volume":"32","author":"Pang","year":"2022","journal-title":"Cell Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/mco2.72","article-title":"A bivalent recombinant vaccine targeting the S1 protein induces neutralizing antibodies against both SARS-CoV-2 variants and wild-type of the virus","volume":"2","author":"He","year":"2021","journal-title":"MedComm"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1229","DOI":"10.1016\/S2214-109X(24)00226-2","article-title":"Delivering safe dengue vaccines","volume":"12","author":"Halstead","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"25151355211015839","DOI":"10.1177\/25151355211015839","article-title":"Dengvaxia: The world\u2019s first vaccine for prevention of secondary dengue","volume":"9","author":"Tully","year":"2021","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"ref_39","first-page":"351","article-title":"Dissecting antibodies induced by a chimeric yellow fever-dengue, live-attenuated, tetravalent dengue vaccine (CYD-TDV) in na\u00efve and dengue exposed individuals","volume":"15","author":"Henein","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(14)61060-6","article-title":"Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: A phase 3, randomised, observer-masked, placebo-controlled trial","volume":"384","author":"Capeding","year":"2014","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Gallichotte, E.N., Baric, T.J., Yount, B.L., Widman, D.G., Durbin, A., Whitehead, S., Baric, R.S., and de Silva, A.M. (2018). Human dengue virus serotype 2 neutralizing antibodies target two distinct quaternary epitopes. PLoS Pathog., 14.","DOI":"10.1371\/journal.ppat.1006934"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1016\/j.vaccine.2011.07.021","article-title":"The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease","volume":"29","author":"Coller","year":"2011","journal-title":"Vaccine"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Lai, Y.-C., Chuang, Y.-C., Liu, C.-C., Ho, T.-S., Lin, Y.-S., Anderson, R., and Yeh, T.-M. (2017). Antibodies Against Modified NS1 Wing Domain Peptide Protect Against Dengue Virus Infection. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-07308-3"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"304ra141","DOI":"10.1126\/scitranslmed.aaa3787","article-title":"Dengue virus NS1 triggers endothelial permeability and vascular leak that is prevented by NS1 vaccination","volume":"7","author":"Beatty","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. (2023). Application of DNA Replicons in Gene Therapy and Vaccine Development. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15030947"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-021-00390-9","article-title":"An alphavirus replicon-based vaccine expressing a stabilized Spike antigen induces protective immunity and prevents transmission of SARS-CoV-2 between cats","volume":"6","author":"Langereis","year":"2021","journal-title":"Npj Vaccines"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm813","article-title":"Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways","volume":"9","author":"Leitner","year":"2003","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ymthe.2019.09.009","article-title":"A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity","volume":"28","author":"Beissert","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6439","DOI":"10.1128\/jvi.67.11.6439-6446.1993","article-title":"Sindbis Virus Expression Vectors\u2014Packaging of Rna Replicons by Using Defective Helper Rnas","volume":"67","author":"Bredenbeek","year":"1993","journal-title":"J. Virol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1016\/j.cub.2013.12.009","article-title":"Generation of infectious virus particles from inducible transgenic genomes","volume":"24","author":"Wernet","year":"2014","journal-title":"Curr. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: An exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"eabo4100","DOI":"10.1126\/sciadv.abo4100","article-title":"A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus","volume":"9","author":"Wang","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"eabq8276","DOI":"10.1126\/sciadv.abq8276","article-title":"Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response","volume":"8","author":"Dickey","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41422-022-00753-4","article-title":"Towards developing a variant-proof SARS-CoV-2 vaccine","volume":"33","author":"Peng","year":"2023","journal-title":"Cell Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nbt0698-562","article-title":"Enhancing immune responses using suicidal DNA vaccines","volume":"16","author":"Berglund","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e00055-19","DOI":"10.1128\/JVI.00055-19","article-title":"Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV","volume":"93","author":"Ljungberg","year":"2019","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1099\/vir.0.80481-0","article-title":"Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1","volume":"86","author":"Forsell","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e1487913","DOI":"10.1080\/2162402X.2018.1487913","article-title":"Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens","volume":"7","author":"Ljungberg","year":"2018","journal-title":"OncoImmunology"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Szurgot, I., Hanke, L., Sheward, D.J., Vidakovics, L.P., Murrell, B., McInerney, G.M., and Liljestr\u00f6m, P. (2021). DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-82498-5"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"eabc9396","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARSCoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.ymthe.2021.04.001","article-title":"A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice","volume":"29","author":"Gan","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105090","DOI":"10.1016\/j.antiviral.2021.105090","article-title":"Viral replicon particles protect IFNAR\u2212\/\u2212 mice against lethal Crimean-Congo hemorrhagic fever virus challenge three days after vaccination","volume":"191","author":"Spengler","year":"2021","journal-title":"Antivir. Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Peiris, J., Deming, D., Sheahan, T., Heise, M., Yount, B., Davis, N., Sims, A., Suthar, M., Harkema, J., and Whitmore, A. (2006). Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030525"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1365-2893.2012.01594.x","article-title":"Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre-S1 antigens induce broadly reactive neutralizing antibodies","volume":"19","author":"Bogdanova","year":"2012","journal-title":"J. Viral Hepat."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/0264-410X(94)90074-4","article-title":"Self-replicating Semliki Forest virus RNA as recombinant vaccine","volume":"12","author":"Zhou","year":"1994","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1080\/21645515.2021.2007711","article-title":"BCG vaccination strategies against tuberculosis: Updates and perspectives","volume":"17","author":"Qu","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Kozak, M., and Hu, J. (2024). DNA Vaccines: Their Formulations, Engineering and Delivery. Vaccines, 12.","DOI":"10.3390\/vaccines12010071"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41541-021-00419-z","article-title":"Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2","volume":"6","author":"Lassauniere","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/rmv.360","article-title":"Alphavirus vectors and vaccination","volume":"12","author":"Rayner","year":"2002","journal-title":"Rev. Med. Virol."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1292\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:35:07Z","timestamp":1760114107000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/11\/1292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":71,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["vaccines12111292"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12111292","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]}}}